Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 26 points (0.2%) at 15,572 as of Tuesday, July 23, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,636 issues advancing vs. 1,285 declining with 117 unchanged. The Health Care sector currently is unchanged today versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the sector include Waters Corporation ( WAT), down 5.9%, Boston Scientific ( BSX), down 2.4%, Alexion Pharmaceuticals ( ALXN), down 2.0%, Vertex Pharmaceuticals ( VRTX), down 1.0% and Sanofi ( SNY), down 0.6%. TheStreet would like to highlight 5 stocks pushing the sector lower today: 5. Actavis ( ACT) is one of the companies pushing the Health Care sector lower today. As of noon trading, Actavis is down $1.40 (-1.1%) to $126.53 on light volume. Thus far, 443,120 shares of Actavis exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $125.65-$128.53 after having opened the day at $128.29 as compared to the previous trading day's close of $127.93. Actavis, Inc., an integrated specialty pharmaceutical company, engages in developing, manufacturing, marketing, selling, and distributing generic, branded generic, brand, biosimilar, and over-the-counter pharmaceutical products worldwide. Actavis has a market cap of $16.0 billion and is part of the drugs industry. Shares are up 48.8% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Actavis a buy, no analysts rate it a sell, and 6 rate it a hold. TheStreet Ratings rates Actavis as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Actavis Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.